by ltsiwpadmin | Jun 30, 2017 | Overview & Epidemiology, Publications
Abstract Mitochondrial dysfunction is closely associated with the pathogenesis of nonalcoholic steatohepatitis (NASH). The aim of the present study was to comprehensively determine mitochondrial abnormalities in NASH by detecting the proteomics in liver mitochondria...
by ltsiwpadmin | Jun 26, 2017 | News
By Zacks Equity Research, Zacks.com June 26, 2017 We issued an updated research report on Allergan plc AGN on Jun 23. Acquisitions form an integral part of Allergan’s expansion strategy. Allergan is reshaping its portfolio through strategic acquisitions. With...
by ltsiwpadmin | Jun 23, 2017 | News
By Anne Steele Published June 23, 2017 The next frontier for multibillion-dollar drug therapies is a silent disease many people don’t know they have. Dozens of pharmaceutical companies including Gilead Sciences Inc., Allergan PLC and Intercept Pharmaceuticals...
by ltsiwpadmin | Jun 15, 2017 | News
By Chris Lieu The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) announced several partnerships, including collaborations concerning obesity, non-alcoholic steatohepatitis and rheumatoid arthritis. J&J’s Janssen Pharmaceuticals...
by ltsiwpadmin | Jun 12, 2017 | News
Regulus Therapeutics acknowledged today that clinical development of its nonalcoholic steatohepatitis (NASH) candidate AZD4076 (RG-125) is being halted by AstraZeneca—one of three Regulus pipeline candidates whose clinical programs are being scuttled. Regulus said...
Recent Comments